VX-509
Sponsors
Vertex Pharmaceuticals Incorporated
Conditions
Drug InteractionsHealthyRheumatoid Arthritis
Phase 1
Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects
CompletedNCT00789126
Start: 2008-10-31Target: 72Updated: 2009-02-19
Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects
CompletedNCT01886209
Start: 2013-06-30End: 2013-08-31Target: 28Updated: 2013-08-14
Phase 2
A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
CompletedNCT01052194
Start: 2010-02-28End: 2011-07-31Updated: 2012-12-13
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
CompletedNCT01590459
Start: 2012-04-30End: 2014-07-31Updated: 2015-11-20
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor
CompletedNCT01754935
Start: 2013-01-31End: 2014-02-28Updated: 2015-05-19
A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis
CompletedNCT01830985
Start: 2013-04-30End: 2014-07-31Updated: 2015-11-20